Maze Therapeutics, Inc..
MAZE.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Maze Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for genetically defined diseases. The company utilizes its proprietary COMPASS platform, a data-driven approach integrating human genetics and functional genomics, to ide...Show More
Better Health for All
0
No evidence available to assess Maze Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Maze Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines, not a financial institution.
1
The value 'Fair Money & Economic Opportunity' primarily assesses companies involved in lending, insuring, moving, or storing money. As Maze Therapeutics does not offer financial products or services to consumers,
2
all KPIs related to financial inclusion, pricing, fees, lending practices, customer financial outcomes, and financial literacy initiatives are not applicable to its core business model. Therefore, the rubric's '0' tier for 'Not applicable' is consistently applied across all KPIs.
Fair Pay & Worker Respect
0
No quantitative data relevant to the Fair Pay & Worker Respect KPIs was found in the provided articles for Maze Therapeutics, Inc. The articles explicitly state that metrics such as living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, and health insurance coverage are not mentioned or provided.
1
While some articles include qualitative employee feedback and general salary ranges, these do not constitute specific, measurable data points for the defined KPIs.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Maze Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-50
Maze Therapeutics has a Whistleblower Policy, approved December 9, 2024, which allows employees to report concerns anonymously and explicitly prohibits retaliation.
1
However, there is no evidence of independent investigation processes or specific metrics on policy communication or usage. The company's Corporate Governance Guidelines, approved December 9, 2024, require a majority of directors to be independent and all board committees to be comprised entirely of independent directors.
2
The company states compliance with the Foreign Corrupt Practices Act (FCPA) and has an Anti-Corruption Policy, but the articles do not detail the frequency or effectiveness metrics of related training.
3
Kind to Animals
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to the 'Kind to Animals' value for Maze Therapeutics, Inc. The documents primarily focus on financial, business, and general ethical conduct, or discuss broader industry trends and regulatory changes without direct application to the company's specific animal welfare practices, policies, or measurable impacts. While 'preclinical in vivo studies' are mentioned, no details on animal testing volume, policy, or alternative methods used by Maze Therapeutics, Inc. are provided.
1
No War, No Weapons
0
Maze Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for genetically defined diseases.
1
The provided articles, which include press releases and SEC filings, consistently describe the company's activities as related to drug development and clinical trials. No information or specific data points were found in any of the articles regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or any other war or weapons-related activities.
2
Consequently, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
The provided articles, including the company's own website and financial summaries, do not contain any specific, concrete data points related to environmental performance or planet-friendly business practices for MAZE.US. Information on greenhouse gas emissions, renewable energy use, water consumption, waste diversion, green building certifications, climate targets, or any other environmental metrics is explicitly stated as 'No data provided' or 'No quantitative data... were found' across all relevant KPIs.
1
Respect for Cultures & Communities
0
The company's Code of Business Conduct and Ethics indicates that Free, Prior, and Informed Consent (FPIC) processes are not applicable to its operations, as it does not directly discuss indigenous communities.
1
Similarly, the company does not discuss indigenous communities directly in relation to indigenous suppliers, suggesting this is not applicable to its operations.
2
Safe & Smart Tech
-30
The company has no documented data breaches and prohibits unauthorized data use, aligning with standard practices.
1
It is SOC2 certified and states GDPR compliance.
2
Users are granted rights to confirm, access, correct, delete, restrict processing, and withdraw consent for their personal information, which indicates excellent privacy controls.
3
However, authentication security is weak, with users responsible for password security and MFA available for less than 20% of services.
4
The company conducts annual vulnerability assessments and patches critical vulnerabilities within 30-45 days on average.
5
Data minimization practices include collecting the minimum necessary personal information and disposing of it when no longer needed, with an aim to de-identify data.
6
The company is subject to stringent and changing data privacy and security obligations, including GDPR, Washington MHMDA, and Nevada SB 370, but compliance is noted to have some implementation gaps.
7
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding Maze Therapeutics' waste management, product recyclability, packaging sustainability, or any other metrics related to the 'Zero Waste & Sustainable Products' ethical value.
1
The articles primarily discuss financial performance, clinical trials, and IPO details, explicitly stating 'No data found' or 'No data relevant to waste management, sustainable products, or circular economy principles' for the relevant KPIs.
2